Continuous lenalidomide shot for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new way to give lenalidomide (Revlimid) as a continuous shot under the skin (subcutaneous infusion) for people with multiple myeloma that has come back or not responded after at least one prior treatment. The goal is to see if this method works better and is easier to tolerate than the standard pill form.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have not had a stem cell transplant for your myeloma
- Your myeloma has gotten worse after at least one prior treatment, and you are now starting a new treatment that includes lenalidomide, dexamethasone, and a proteasome inhibitor (like bortezomib or carfilzomib)
- You have measurable signs of myeloma in your blood or urine after your last treatment
- You are willing to follow strict birth control rules if you or your partner could become pregnant, and you are willing to take blood thinners to prevent clots
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
This trial tests a combination of three drugs (elranatamab, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma. The goal is to see if this treatment can lead to a very deep response (no detectable cancer cells) in the bone marrow.
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
This trial tests a new drug combined with other medicines for people with multiple myeloma, a related condition called AL amyloidosis, or high-risk smoldering multiple myeloma. It aims to see if the combination is safe and effective.
This trial tests a combination of three drugs (CM336, daratumumab, and lenalidomide) for people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if this combination is safe and effective in controlling the disease.
This trial tests adding a new drug, linvoseltamab, to the standard maintenance therapy lenalidomide for people with newly diagnosed multiple myeloma. The goal is to see if it can deepen responses or turn a relapse back to a negative minimal residual disease (MRD) state, where no cancer cells are detectable.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.